证券代码：688046 证券简称：药康生物 编号：2022-001 投资者关系活动记录表 江苏集萃药康生物科技股份有限公司 | --- | --- | --- | |----------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者活动关系 | | ...

投资者关系活动记录表 证券代码：688046 证券简称：药康生物 编号：2022-003 江苏集萃药康生物科技股份有限公司 | --- | --- | --- | |-----------------------------|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者活动关系 | | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥135,914,412.02, representing a year-over-year increase of 34.21%[6] - The net profit attributable to shareholders for Q3 2022 was ¥46,491,112.41, reflecting an 18.98% increase compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥23,181,972.53, up 38.50% year-over-year[6] - The increase in net profit for the year-to-date period was attributed to higher sales revenue and increased government subsidies compared to the previous year[18] - The company's net profit attributable to shareholders increased to ¥257,969,402.05, compared to ¥129,843,276.84 in the same period last year, marking a growth of 99%[38] - The company's net profit for the third quarter of 2022 was CNY 128,126,125.21, an increase of 50.0% compared to CNY 85,416,398.54 in the same period of 2021[41] - The total comprehensive income for the third quarter was CNY 128,816,522.89, compared to CNY 85,949,159.59 in the same quarter of the previous year, marking a growth of 49.8%[42] Research and Development - Research and development expenses for Q3 2022 totaled ¥22,921,127.94, a significant increase of 58.79% compared to the same period last year[10] - The company plans to continue expanding its R&D efforts, focusing on large-scale projects such as "spot mice" and "real-world animal models" to drive future growth[20] - Research and development expenses amounted to ¥61,531,906.43, a significant rise of 62% from ¥38,097,614.91 in the previous year[38] Assets and Equity - Total assets at the end of Q3 2022 reached ¥2,198,953,073.60, marking a substantial increase of 108.55% from the end of the previous year[10] - The equity attributable to shareholders at the end of Q3 2022 was ¥1,940,551,703.82, which is a 147.00% increase compared to the previous year-end[10] - Total assets reached ¥2,198,953,073.60, up from ¥1,054,409,220.49, reflecting a growth of 108%[36] - The company's equity attributable to shareholders increased to ¥1,940,551,703.82, compared to ¥785,633,044.20, a growth of 147%[38] Shareholder Information - Total number of common shareholders at the end of the reporting period was 5,958[21] - The largest shareholder, Nanjing Laoyan Venture Capital Partnership, holds 201,817,185 shares, accounting for 49.22% of total shares[21] - The second largest shareholder, Qingdao Guoyao Dachuang Investment Partnership, holds 34,745,078 shares, representing 8.47%[21] - The top ten shareholders include various investment funds, with the largest being China Industrial Bank's mixed securities investment fund holding 6,606,462 shares[26] - The company has not disclosed any significant related party transactions among the top ten shareholders[28] Cash Flow and Financial Stability - The company's cash and cash equivalents as of September 30, 2022, amounted to ¥355,857,001.38, an increase from ¥293,517,395.01 at the end of 2021[30] - Cash and cash equivalents increased significantly, contributing to improved liquidity and financial stability[36] - Cash flow from operating activities generated a net inflow of CNY 46,996,531.16, an increase from CNY 37,986,022.69 in the prior year[47] - The company reported a significant increase in cash and cash equivalents, ending the quarter with CNY 355,757,001.38, compared to CNY 187,105,204.79 at the end of the same quarter last year[49] - Investment activities resulted in a net cash outflow of CNY 990,833,403.54, compared to a smaller outflow of CNY 390,365,635.46 in the previous year[49] - The company received CNY 1,029,513,457.49 from financing activities, indicating strong capital inflow compared to CNY 25,000,000.00 in the same period last year[49] Operating Costs - Total operating costs for the first three quarters of 2022 were ¥285,523,134.45, up from ¥202,941,108.39, reflecting a 41% increase[38] - Accounts receivable rose to ¥190,355,407.96, compared to ¥118,571,037.55, indicating an increase of 60%[33] - Inventory increased to ¥46,586,371.56 from ¥30,083,605.37, representing a growth of 55%[33] Financial Statements and Caution - The financial statements for the quarter are unaudited, indicating a need for caution in interpreting the results[29] - The company has not participated in any margin trading or securities lending activities as per the information available[28] - The company reported a decrease in credit impairment losses, which improved to CNY -4,869,853.19 from CNY -6,828,585.99 in the previous year[41]

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a 20% increase compared to the same period last year[2]. - The company reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[19]. - The company achieved total revenue of 250.37 million yuan, a year-on-year increase of 40.29%, and a net profit attributable to shareholders of 81.64 million yuan, up 76.16% year-on-year[129]. - The company reported a total revenue of 53,400 million RMB, with a net profit of 3,861.08 million RMB for the first half of 2022[119]. - The gross margin improved to 45%, up from 40% in the same period last year, reflecting better cost management and pricing strategies[19]. - The net profit attributable to shareholders was ¥81,635,012.80, a 76.16% increase from ¥46,341,369.79 year-on-year[32]. - The net cash flow from operating activities increased by 111.37% to ¥22,135,482.77, up from ¥10,472,319.95 in the previous year[32]. - The company's total assets grew to ¥2,176,019,760.00, a 106.37% increase from ¥1,054,409,220.49 at the end of the previous year[32]. - The company's cash flow from operating activities increased by 111.37% to CNY 22.14 million[154]. - The company recognized government subsidies of CNY 25.68 million, accounting for 27.52% of the total profit for the reporting period[151]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching 1.2 million users by the end of June 2022[2]. - User data showed an increase in active users by 20% compared to the previous year, reaching 5 million active users[19]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[2]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[19]. - The overseas market generated revenue of 24.87 million yuan, accounting for 9.93% of total revenue, with a year-on-year growth of 98.40%[130]. Research and Development - Investment in R&D increased by 25% year-on-year, focusing on new technologies and product development[19]. - The R&D expenditure as a percentage of revenue increased to 15.42%, up from 13.26% year-on-year, indicating a focus on innovation[35]. - The company achieved a total R&D investment of ¥38,610,778.49, representing a year-on-year increase of 63.17%[106]. - The company published a total of 1,071 SCI articles with a cumulative impact factor of 9,978.5, including 390 articles published during the reporting period with an impact factor of 3,511.9[103]. - The company has developed over 20,000 proprietary commercial mouse models, maintaining a leading position in the industry[124]. - The company is currently undertaking four major scientific research projects, including the National Genetic Engineering Mouse Resource Bank and gene-modified animal models for cardiovascular and metabolic diseases[100]. Product Development and Innovation - New product development includes the launch of two innovative drug candidates, expected to enter clinical trials by Q4 2022[2]. - The company is set to launch two new products in Q4 2022, anticipated to contribute an additional RMB 300 million in revenue[19]. - The company has created an innovative drug screening and phenotypic analysis platform, providing comprehensive in vivo and in vitro evaluation services for drug efficacy and mechanisms[47]. - The company has developed several innovative models, including NCG-IL15 and K18-hACE2, leading the industry in model creation capabilities and product quality[76]. - The company is advancing its new generation model development, including "Drug Screening Mice" and "Germ-Free Mice," positioning itself as a leader in the industry[125]. Strategic Acquisitions and Partnerships - A strategic acquisition of a biotech firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional 50 million RMB in revenue annually[2]. - A strategic acquisition of a smaller biotech firm was announced, expected to enhance the company's product pipeline and innovation capabilities[19]. - A new partnership with a leading research institution was established to accelerate the development of next-generation therapies[19]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[5]. - The company faces risks related to the uncertainty of CRISPR/Cas9 technology licensing and potential increases in costs if alternative technologies are required[145]. Environmental and Compliance Practices - The company has maintained a good environmental compliance record with no administrative penalties for environmental issues during the reporting period[175]. - The company employs active carbon adsorption and deodorization devices to treat exhaust gases, ensuring emissions meet standards[177]. - The company promotes sustainable development by advocating for green office practices and resource conservation among employees[178]. - The company has implemented a comprehensive environmental management system in accordance with national regulations[175]. Shareholding and Governance - The company has committed to various shareholding restrictions for major stakeholders, ensuring compliance with lock-up periods[183]. - The controlling shareholder will hold the company's shares long-term and will not reduce holdings within two years after the lock-up period[190]. - The company will ensure compliance with the Shanghai Stock Exchange's regulations on shareholder reductions and management[194]. - The company emphasizes strict adherence to the Securities Law and related regulations to ensure transparent and responsible shareholding practices[198].